RxDoctor Payments DataLook up a doctor →

Christian Shull, MD

Hematology & Oncology · Idaho Falls, IDNPI 1396899134

Payments from drug & device makers

$149,970in general payments, 2019–2025

Across 963 payments — averaging $155.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$65K
  • Sanofi$45K
  • Myriad Genetic Laboratories, Inc.$15K
  • Gilead$7K
  • AstraZeneca$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron Healthcare Solutions, Inc.68$64,822
Sanofi109$44,743
Myriad Genetic Laboratories, Inc.30$15,082
Gilead(2 entities)24$6,571
AstraZeneca65$3,901
Takeda Pharmaceuticals U.S.A., Inc.10$1,595
E.r. Squibb & Sons, L.L.C.86$1,415
Daiichi Sankyo Inc.19$935
Pfizer85$869
Johnson & Johnson(2 entities)26$813
Novartis49$798
Amgen39$712
Astellas Pharma US Inc34$634
Merck31$570
Exelixis Inc.8$532
GSK24$508
Varian Medical Systems, Inc.1$480
AbbVie18$470
Dendreon Pharmaceuticals LLC14$380
EMD Serono, Inc.18$307
Eisai Inc.14$301
Bristol Myers Squibb16$293
Bayer25$227
Tempus AI, Inc2$210
Incyte Corporation9$192
Genentech USA, Inc.12$187
Boehringer Ingelheim8$173
Jazz Pharmaceuticals Inc.7$165
Lilly USA, LLC9$154
AVEO Pharmaceuticals, Inc.5$153
Tersera Therapeutics LLC8$151
Puma Biotechnology, Inc.7$128
Seagen Inc.6$99
Sanofi-aventis U.S. LLC1$85
CTI Biopharma Corp.3$69
Stemline Therapeutics Inc.3$65
Ipsen Biopharmaceuticals, Inc3$58
Beone Medicines USA, Inc.2$58
Sumitomo Pharma America, Inc.3$55
Beigene USA, Inc.3$53
Pharmacyclics LLC, An Abbvie Company3$52
Myovant Sciences Inc.3$48
Clovis Oncology, Inc.5$47
Agios Pharmaceuticals, Inc.3$47
Taiho Oncology, Inc.2$46
Sobi, Inc3$45
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$44
Karyopharm Therapeutics Inc.2$42
Pharmacosmos Therapeutics Inc.2$41
Morphosys, US Inc.2$37
Springworks Therapeutics, Inc.2$36
Helsinn Therapeutics (U.S.), Inc.2$34
Legend Biotech USA Inc.1$33
Acrotech Biopharma Inc.2$32
Blueprint Medicines Corporation2$31
Fresenius Kabi USA, LLC2$30
Organon3$26
EUSA Pharma (US) LLC1$24
Medtronic1$24
Tolmar Pharmaceuticals, Inc.1$23

How this compares

$149,970 in reported general payments places this provider in the 85th percentile of 34 hematology & oncology providers in Idaho.

See all hematology & oncology providers in Idaho →

Medicare billing

Part B allowed, 2024
$69,104
Medicare patients
365
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Idaho Falls

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →